Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators have recently discovered a genetic variant in an adrenergic receptor that leads to increased risk for type 2 diabetes. The investigators have also seen that blockers of that receptor improves impaired insulin secretion in animals. The investigators will now test the blocker in patients with type 2 diabetes with or without the risk variant in an effort to make diabetes treatment more individualized.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Anders Rosengren, MD PhD
• Collaborators: Lund University; Region Skane
• Treatments: Yohimbine

Criteria

Inclusion Criteria:

• type 2 diabetes

• informed consent

• age 18-70, for females only postmenopausal

Exclusion Criteria:

• heart disease

• anxiety disorder

• antidiabetic treatment other than metformin

• adrenergic blockers

• ulcus

• allergy to any component in the capsules